[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus-dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus-dm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,69,98,122,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100659851","phase-2-a-study-of-vct220-tablets-in-adults-with-type-2-diabetes-and-inadequate-blood-glucose-control-100659851",false,"NCT07872436","A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VCT220 Tablets in Adults With Type 2 Diabetes Mellitus Inadequately Controlled With Lifestyle Intervention, Metformin Monotherapy, or Metformin in Combination With an SGLT2 Inhibitor","VICTOR-DM","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 65 years, inclusive, at the time of informed consent.\n2. Type 2 diabetes mellitus diagnosed at least 3 months before screening according to the Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 edition), and meeting one of the following: (a) management with diet and exercise alone for at least 3 months before screening; or (b) oral metformin at a stable dose of ≥1500 mg\u002Fday or a maximum tolerated dose of ≥1000 mg\u002Fday, alone or with an SGLT2 inhibitor at a stable dose, for at least 8 weeks before screening.\n3. HbA1c of 7.5% to 10.5%, inclusive, at screening, as measured by the local laboratory.\n4. Body weight ≥50 kg and body mass index of 19 to 35 kg\u002Fm², inclusive.\n5. Self-reported or documented body weight change of no more than 5% within the 3 months before screening.\n6. Willing and able to maintain a stable residence, remain contactable, and maintain a regular daily routine and diet and exercise management throughout the study.\n7. Fully understands the study procedures, can communicate effectively with the investigator, understands and can comply with study requirements, and is willing to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Previous diagnosis or suspicion of type 1 diabetes, other specific types of diabetes, or secondary diabetes.\n2. Acute complications of diabetes within 6 months before screening, including diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state.\n3. A Level 3 hypoglycemic event or at least three hypoglycemic events within 6 months before screening.\n4. History or current presence of proliferative retinopathy or maculopathy, painful diabetic neuropathy, diabetic foot ulceration, or intermittent claudication.\n5. A hematologic disorder or other condition at screening that may affect HbA1c measurement, including known hemoglobinopathy, hemolytic anemia, sickle cell anemia, blood transfusion within 3 months before screening, or severe blood loss within that period.\n6. Any of the following local laboratory or 12-lead electrocardiogram findings during screening:\n\n   * Fasting plasma glucose \\>11.1 mmol\u002FL.\n   * Thyroid-stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL.\n   * Alanine aminotransferase or aspartate aminotransferase ≥2 times the upper limit of normal (ULN), or total bilirubin ≥2 × ULN.\n   * Fasting triglycerides \\>5.65 mmol\u002FL.\n   * Serum amylase or lipase ≥1.5 × ULN.\n   * Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m².\n   * Calcitonin ≥50 ng\u002FL.\n   * Hemoglobin \\\u003C110 g\u002FL in males or \\\u003C100 g\u002FL in females.\n   * Electrocardiographic heart rate \\\u003C55 or \\>110 beats\u002Fminute.\n   * Second- or third-degree atrioventricular block, long QT syndrome, QTcF \\>450 ms in males or \\>470 ms in females, left bundle branch block, complete right bundle branch block, pre-excitation syndrome, or other clinically significant arrhythmia, except asymptomatic sinus arrhythmia.\n7. Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening.\n8. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.\n9. History or current presence of severe gastrointestinal disease or relevant surgery, including acute or chronic pancreatitis, hepatitis, cholecystitis (except after cholecystectomy), or intestinal obstruction.\n10. Heart failure of New York Heart Association Class III or IV, unstable angina, stroke, myocardial infarction, or coronary revascularization within 6 months before screening; or planned coronary, carotid, or peripheral arterial revascularization at screening.\n11. Acute infection within 2 weeks before screening.\n12. Any malignancy within the previous 5 years or currently, except cured basal cell carcinoma of the skin or cervical carcinoma in situ.\n13. History or current presence of a condition that may require repeated or long-term systemic glucocorticoid therapy, such as systemic lupus erythematosus, inflammatory bowel disease, or asthma. Topical, intraocular, and intranasal glucocorticoids are excluded from this restriction.\n14. Known or suspected allergy to VCT220 tablets, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or excipients.\n15. Previous discontinuation of a GLP-1 RA because of safety or tolerability concerns.\n16. Insulin treatment within 3 months before screening, or treatment with any glucose-lowering medication other than metformin or an SGLT2 inhibitor during that period, including traditional Chinese medicines used to lower blood glucose.\n17. Positive hepatitis B surface antigen at screening, except when quantitative hepatitis B virus DNA is below the lower limit of the assay reference range and the participant is not receiving anti-hepatitis B medication at screening; or positive hepatitis C virus antibody, human immunodeficiency virus antibody, or syphilis antibody.\n18. Significantly active or unstable major depressive disorder or another severe psychiatric disorder within 2 years before screening, or any history of attempted suicide.\n19. History of alcohol or drug abuse within 3 months before screening. Alcohol abuse is defined as more than 7 units per week; one unit is 360 mL of beer containing 5% alcohol, 45 mL of spirits containing 40% alcohol, or 150 mL of wine containing 12% alcohol.\n20. Treatment with any other investigational product within 3 months or 5 half-lives before screening, whichever is longer, or plans to participate in another clinical trial during this study.\n21. Pregnancy or breastfeeding; a male or female participant of reproductive potential unwilling to use highly effective contraception throughout the study and for 3 months after the last dose; plans to conceive or donate sperm or oocytes during that period; or a positive pregnancy test during screening.\n22. An employee of the sponsor, a study site, or the contract research organization, or an immediate family member of such an employee.\n23. Considered unsuitable for study participation by the study site.","ALL","18 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin combined with a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The study will also assess safety, tolerability, and how VCT220 is processed by the body.\n\nApproximately 120 participants will be randomly assigned in equal proportions to VCT220 40 mg, 80 mg, 120 mg, or placebo, taken orally once daily for 16 weeks. Higher-dose groups will start at 40 mg and increase the dose in steps. Participation will last approximately 22 weeks, including screening, a placebo run-in period, treatment, and safety follow-up. The main assessment is the change in glycated hemoglobin (HbA1c) from baseline to Week 16.",[28],"Type 2 Diabetes Mellitus (DM)","NOT_YET_RECRUITING","2026-10-08",{"date":32,"type":33},"2026-10-13","ACTUAL",{"date":35,"type":22},"2026-11-01",{"date":37,"type":22},"2027-09-01",{"name":39,"class":40},"Vincentage Pharma Co., Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100658765","effect-of-otago-vs-sensorimotor-training-on-balance-and-fall-risk-in-people-with-diabetes-100658765","NCT07854496","Effect of Otago vs. Sensorimotor Training on Balance and Fall Risk in People With Diabetes","OTAGO VERSUS SENSORIMOTOR TRAINING ON DYNAMIC POSTURAL STABILITY AND RISK OF FALL IN DIABETIC PATIENTS.","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus for at least 5 years.\n* Body Mass Index (BMI) ranging from 18.0 to 27.4 kg\u002Fm2.\n* Age between 45 and 55 years.\n* Clinically and medically stable.\n* Able to ambulate independently without assistive devices.\n* Mild to moderate balance impairment based on the Mini-BESTest score.\n* Glycated Hemoglobin (HbA1c) level of 6.5% or higher.\n\nExclusion Criteria:\n\n* Severe diabetic complications (e.g., advanced neuropathy with complete loss of protective sensation, active foot ulcers, or lower limb amputations).\n* Neurological disorders affecting balance other than diabetic neuropathy (e.g., stroke, Parkinson's disease, or multiple sclerosis).\n* Musculoskeletal conditions severely affecting lower limb function (e.g., severe osteoarthritis, recent lower limb fractures, or major orthopedic surgery).\n* Severe visual impairment not corrected by glasses or corrective lenses.\n* Vestibular disorders causing balance impairment or acute dizziness.\n* Significant liver or renal impairment.\n* Uncontrolled cardiovascular conditions that limit exercise participation or present safety risks during physical activity.\n* Cognitive impairment preventing the ability to understand or follow exercise instructions.\n* Non-compliance or intervention dropouts (e.g., patients missing more than two weeks of sessions or voluntarily withdrawing from the study).","45 Years","55 Years",{"count":52,"type":22},40,[54],"NA","The purpose of this study is to compare the effects of the Otago Exercise Program versus Sensorimotor Training on dynamic postural stability and risk of fall in patients with type 2 diabetes mellitus.\n\nParticipants will be randomly assigned into two equal intervention groups. One group will receive the Otago Exercise Program, while the other group will receive Sensorimotor Training. Both groups will participate in their respective exercise protocols for 8 weeks. Dynamic postural stability and the risk of falling will be assessed before and after the intervention period using standardized physical therapy evaluation tools.",[28,57,58],"Accidental Falls","Postural Balance","2026-09-27",{"date":61,"type":33},"2026-10-02",{"date":63,"type":22},"2026-10-01",{"date":65,"type":22},"2026-12-01",{"name":67,"class":68},"Cairo University","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100657580","preoperative-gastric-volume-and-high-risk-gastric-content-in-patients-with-type-2-diabetes-mellitus-100657580","NCT07842757","Preoperative Gastric Volume and High-Risk Gastric Content in Patients With Type 2 Diabetes Mellitus","Clinical and Metabolic Determinants of High Residual Gastric Volume in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of type 2 diabetes mellitus\n* American Society of Anesthesiologists (ASA) physical status II or III\n* Scheduled for elective surgery\n* Suitable for preoperative gastric ultrasonography\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Body mass index ≥40 kg\u002Fm²\n* Emergency surgery\n* History of gastric, esophageal, or upper gastrointestinal surgery\n* Presence of a nasogastric tube\n* Known gastroparesis or gastric outlet obstruction\n* Active vomiting\n* Systemic opioid or prokinetic drug use within the previous 72 hours\n* Anatomical or technical conditions preventing adequate gastric ultrasonographic assessment\n* Impaired consciousness or inability to provide a reliable medical history\n* Refusal to participate in the study",{"count":21,"type":22},"OBSERVATIONAL","This prospective observational study will evaluate adult patients with type 2 diabetes mellitus who are scheduled for elective surgery. Immediately before preoperative gastric ultrasonography, capillary fasting blood glucose will be measured.\n\nGastric contents will be assessed qualitatively in the supine and right lateral decubitus positions, and residual gastric volume will be estimated using the antral cross-sectional area measured in the right lateral decubitus position.\n\nThe primary objective is to evaluate the association between fasting capillary blood glucose and the presence of a high-risk stomach. A high-risk stomach will be defined as the presence of solid gastric contents, Perlas Grade 2 gastric contents, or an estimated gastric volume greater than 1.5 mL\u002Fkg.\n\nSecondary objectives include determining the prevalence of a high-risk stomach and evaluating its associations with demographic characteristics, diabetes-related factors, comorbidities, fasting duration, medication use, gastroparesis-related symptoms, and routine laboratory parameters.",[28,80],"Gastric Ultrasound",[82,83,84,85,86,87,88],"Gastric Ultrasonography","Preoperative Fasting","Residual Gastric Volume","Fasting Blood Glucose","Gastric Contents","Perlas Grading","Type 2 Diabetes Mellitus","2026-09-26",{"date":91,"type":33},"2026-09-30",{"date":63,"type":22},{"date":94,"type":22},"2027-04-01",{"name":96,"class":97},"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","OTHER_GOV",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100657109","proteome-wide-association-and-llm-based-prioritization-of-type-2-diabetes-protein-targets-100657109","NCT07832656","Proteome-Wide Association and LLM-Based Prioritization of Type 2 Diabetes Protein Targets","Integrative Proteome-Wide Association Study and Large Language Model-Based Prioritization of Causal Protein Targets of Type 2 Diabetes","LAUNCH-T2D","Inclusion Criteria:\n\n* Participants enrolled in the source studies who were aged 40 to 84 years at enrollment.\n* Availability of genetic data and plasma proteomic data for population-specific protein prediction modeling.\n* Participants with or without type 2 diabetes, depending on the source dataset and analytic objective.\n\nExclusion Criteria:\n\n* Participants younger than 40 years or older than 84 years at enrollment in the source studies.\n* Participants lacking genetic data or plasma proteomic data required for protein prediction modeling.\n\nThis study will conduct a retrospective secondary analysis of existing, controlled-access datasets. No new participants will be recruited or contacted. Type 2 diabetes genome-wide association summary statistics will also be used for association analyses; the participant-level eligibility criteria above apply to individual-level source-study records used for protein prediction modeling.",true,"40 Years","84 Years",{"count":110,"type":22},31994,"Type 2 diabetes is a common condition in which the body has difficulty controlling blood sugar. This study will use existing genetic, protein, and health data from prior research studies to identify blood proteins that may play a role in type 2 diabetes. The study will not recruit participants, provide treatment, or collect new samples. Researchers will use computer-based analyses to identify and prioritize protein targets for future laboratory and clinical research. The goal is to support the development of better approaches for understanding, preventing, and treating type 2 diabetes.",[28],"2026-09-23",{"date":115,"type":33},"2026-09-28",{"date":117,"type":22},"2026-09-15",{"date":119,"type":22},"2027-08-02",{"name":121,"class":68},"Louisiana State University Health Sciences Center in New Orleans",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100656903","preoperative-oral-carbohydrate-loading-in-patients-with-type-2-diabetes-undergoing-gastrointestinal-surgery-100656903","NCT07830537","Preoperative Oral Carbohydrate Loading in Patients With Type 2 Diabetes Undergoing Gastrointestinal Surgery","Effects of Preoperative Oral Carbohydrate Loading on Postoperative Insulin Resistance and Glycemic Stability in Patients With Type 2 Diabetes Undergoing Elective Gastrointestinal Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1.Age 18 to 75 years, regardless of sex. 2.Diagnosis of type 2 diabetes mellitus. 3.Glycated hemoglobin (HbA1c) ≤8.0%, with preoperative fasting plasma glucose generally ≤10.0 mmol\u002FL.\n\n  4.Scheduled to undergo elective gastrointestinal surgery. 5.Able to wear a continuous glucose monitoring (CGM) device for at least 24 hours before surgery and willing to continue monitoring until hospital discharge or the protocol-specified time point.\n\n  6.Able to understand the study procedures, voluntarily participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Known or highly suspected diabetic gastroparesis, delayed gastric emptying, gastric outlet obstruction, or upper gastrointestinal obstruction.\n\n  2\\. Severe gastroesophageal reflux disease or other conditions considered by the investigator to confer a high risk of aspiration.\n\n  3\\. Emergency surgery or other non-elective surgery for which the study intervention cannot be implemented as planned.\n\n  4\\. Type 1 diabetes mellitus, gestational diabetes mellitus, or other specific types of diabetes.\n\n  5\\. Pregnancy or breastfeeding. 6. Recent systemic glucocorticoid therapy. 7. Severe hepatic or renal dysfunction, or active severe infection. 8. Inability to comply with CGM use, cognitive or psychiatric conditions preventing completion of study assessments, or anticipated poor adherence to the study protocol.\n\n  9\\. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.","75 Years",{"count":131,"type":22},126,[54],"This study is a single-center randomized controlled trial in adults with type 2 diabetes who are scheduled for elective gastrointestinal surgery. The study aims to find out whether drinking a carbohydrate-containing clear liquid before surgery can reduce early postoperative insulin resistance and improve blood glucose stability without increasing the risk of high or low blood glucose.\n\nParticipants will be randomly assigned in a 1:1:1 ratio to one of three groups. The first group will receive standard enhanced recovery after surgery (ERAS) fasting and clear-fluid management without a carbohydrate-containing drink. The second group will drink 400 mL of a 12.5% maltodextrin carbohydrate solution, providing about 50 g of carbohydrate, approximately 2 hours before anesthesia. The third group will receive 500 mL of 10% glucose solution intravenously over approximately 2 hours before anesthesia. The intravenous glucose group is included mainly to help explore whether the route of carbohydrate administration affects the metabolic response.\n\nAll participants will receive standard perioperative care. Blood glucose will be monitored during the perioperative period, including continuous glucose monitoring when available, with point-of-care blood glucose testing used to confirm clinically important high or low glucose readings and to guide treatment when necessary.\n\nThe primary outcome is insulin resistance on the first day after surgery, measured using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), which is calculated from fasting blood glucose and fasting insulin concentrations. Secondary outcomes include perioperative glucose levels and glucose variability, time spent within, above, and below the target glucose range, insulin and C-peptide levels, postoperative nausea and vomiting, patient comfort, postoperative recovery, hospital stay, postoperative complications, and safety events such as hypoglycemia, severe hyperglycemia, reflux, or aspiration.\n\nThe main comparison of interest is between the oral carbohydrate group and the standard ERAS group. The intravenous glucose group will be analyzed mainly as a mechanistic exploratory group.",[28,135],"Gastrointestinal Surgery",[137,88,135,138,139,140],"Preoperative Carbohydrate Loading","Enhanced Recovery After Surgery","HOMA-IR","Continuous Glucose Monitoring",{"date":142,"type":33},"2026-09-21",{"date":63,"type":22},{"date":145,"type":22},"2027-12-30",{"name":147,"class":68},"The Affiliated Hospital of Qingdao University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":41},"100656575","mulligan-mobilization-with-movement-versus-conventional-physiotherapy-on-ankle-range-of-motion-mobility-pain-and-quality-of-life-in-patients-with-type-2-diabetes-mellitus-100656575","NCT07827625","Mulligan Mobilization With Movement Versus Conventional Physiotherapy on Ankle Range of Motion, Mobility, Pain, and Quality of Life in Patients With Type 2 Diabetes Mellitus","Comparative Effects of Mulligan Mobilization With Movement and Conventional Physiotherapy on Ankle Range of Motion, Mobility, Pain, and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 50-70 years\n* Both male and female\n* Diabetes Mellitus \\> 5 years' duration\n* Willing to participate and provide informed consent\n* Pain rated between 3-7 on the Numeric Pain Rating Scale (NPRS)\n* Ankle dorsiflexion range of motion ≤10° on goniometric assessment\n\nExclusion Criteria:\n\n* History of recent lower-limb surgery, fracture, or dislocation (\\\u003C6 months)\n* Active diabetic foot ulcer or Charcot foot\n* Any inflammatory joint disease (e.g., rheumatoid arthritis)\n* Congenital foot deformity\n* Diagnosed diabetic peripheral neuropathy","50 Years","70 Years",{"count":158,"type":22},56,[54],"Type 2 Diabetes Mellitus (T2DM) is a major global health concern associated with chronic hyperglycemia, oxidative stress, and accumulation of advanced glycation end-products, which impair connective tissue function and commonly restrict ankle (tibiotalar) mobility. Reduced ankle range of motion, neuropathic pain, and gait instability significantly impair daily activities and quality of life in this population, and reduced ankle mobility is further associated with increased risk of diabetic foot ulceration. Conventional physiotherapy is widely used to address these impairments through exercise, stretching, and strengthening, but may not fully resolve mechanical joint restrictions. Mulligan's Mobilization with Movement (MWM) is a manual therapy technique in which a sustained glide is applied to the ankle during active weight-bearing movement, correcting positional faults and improving dorsiflexion range of motion. While MWM has shown benefit in non-diabetic ankle conditions, its effectiveness relative to conventional physiotherapy in patients with T2DM remains unclear.\n\nThis study is a randomized controlled trial comparing the effects of Mulligan Mobilization with Movement (Group A) versus conventional physiotherapy (Group B) on pain intensity, ankle range of motion, functional mobility, and quality of life in adults aged 50-70 years with Type 2 Diabetes Mellitus of more than 5 years' duration. A total of 56 participants will be recruited using non-probability purposive sampling and randomly allocated by coin-toss method into two equal groups of 28. Both groups will receive baseline treatment (hot pack application and gentle active ankle movement) followed by their assigned protocol - Group A receiving MWM (sustained anteroposterior\u002Fposteroanterior glide to the distal tibia or fibula during active dorsiflexion or plantarflexion, 3 sets of 10 repetitions) and Group B receiving conventional physiotherapy (active\u002Fpassive range-of-motion exercises, calf raises, and calf\u002FAchilles stretching) - three sessions per week for six weeks.\n\nOutcomes will be assessed at baseline and following the six-week intervention period. Primary outcome measures include pain intensity (Numeric Pain Rating Scale), ankle range of motion (goniometer), functional mobility (Timed Up and Go test), and quality of life (SF-12 Health Survey). Data will be analyzed using IBM SPSS Statistics version 27, with normality assessed via the Shapiro-Wilk test and within- and between-group comparisons made using parametric or non-parametric tests as appropriate.\n\nThis trial is expected to generate direct comparative evidence on whether Mulligan Mobilization with Movement offers superior outcomes to conventional physiotherapy for ankle-related impairments in patients with T2DM, helping physiotherapists select more targeted, evidence-based rehabilitation protocols for this population.",[28],[163,164,165,166],"Mulligan Mobilization with Movement","ankle range of motion","quality of life","pain","RECRUITING","2026-09-14",{"date":170,"type":33},"2026-09-18",{"date":172,"type":33},"2026-03-02",{"date":174,"type":22},"2026-10-05",{"name":176,"class":68},"Ibadat International University, Islamabad"]